DDInter350 DDInter1105
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) causes {v} (Side Effect) Digestion impaired
Digestion impaired {u} (Side Effect) is caused by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) binds {v} (Gene) GSTP1
GSTP1 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Chlorambucil {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) causes Digestion impaired (Side Effect) and Digestion impaired (Side Effect) is caused by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Lurbinectedin
Chlorambucil (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Lurbinectedin
Chlorambucil (Compound) binds GSTP1 (Gene) and GSTP1 (Gene) is bound by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Chlorambucil (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin